FDA Approves Replimune Melanoma Drug & Medicare Policy Delay Raises Costs
The U.S. Food and Drug Administration granted accelerated approval to Replimune’s advanced melanoma treatment, to be marketed as Tudriqev, following an advisory committee’s supportive vote. Simultaneously, a consumer advocacy group ... Read More